doi:10.1038/s41598-023-43587-9 Spreckley M, Ruggiero CF, Brown A
Key takeaways for clinicians: Significant weight reduction and glycemic improvement within 7 months No psychiatric destabilization , addressing a key safety concern Could redefine metabolic management in antipsychotic-treated patients Supports integration of GLP-1 agonists into psychiatry-endocrinology collaboration models References Ganeshalingam AA, Uhrenholt N, Arnfred S, et al
( E H ) GLP-1 and SS output (fmol/min) or mean incremental output (fmol/20 min) in response to glucose and glucose + SSTR5a in C57BL/6JRj mice (GLP-1 and SS: n = 6)
Next, any data points with a standardized value less than the negative of the maximum standardized value (i.e., 5.5) were assigned to 5.5
Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI
Membership primary care Flexible appointments